Quick Facts: Лефомид (Leflunomide) Therapeutic Use

• Main Indication: Management of active Rheumatoid Arthritis (RA) in adults.
• Supportive Use: May be considered for managing active Psoriatic Arthritis.
• Primary Benefit: Helps to reduce clinical signs and symptoms associated with the condition.
• Structural Impact: May slow the progression of structural joint damage, as shown by X-ray evidence.
• Functional Goal: Can support the improvement of physical function and mobility in patients.

---

Лефомид (Leflunomide) is a medication approved for the treatment of active rheumatoid arthritis (RA) in adult patients. For this patient population, its use is intended to assist in the management of the condition's impact on joints.

The use of Лефомид may contribute to a reduction in certain clinical manifestations of active RA, such as joint swelling and tenderness. Furthermore, it is associated with a potential to slow the rate of structural joint damage and erosions, which is a key consideration in long-term disease management. By supporting these outcomes, the treatment may help promote improvement in physical function and overall quality of life.

This agent may also be considered for use in the management of active psoriatic arthritis. Decisions regarding the initiation of this therapy should be made in consultation with a qualified healthcare provider. The patient response to treatment will vary based on individual circumstances and the specific nature of the condition.

Who Can and Cannot Use Лефомид?

This section details the officially documented population eligibility and non-eligibility rules for Лефомид (Leflunomide), as defined by government regulatory agencies.

Contraindicated Populations (Must Not Use)

Лефомид is strictly contraindicated by regulatory bodies in the following groups:

• Pregnant women and women of childbearing potential not using reliable contraception.
• Breastfeeding women.
• Patients with severe hepatic impairment or pre-existing acute or chronic liver disease, including those with elevated liver enzymes (ALT >2x ULN) before treatment initiation.
• Patients with a known hypersensitivity to leflunomide or its active metabolite, teriflunomide.
• Patients with severe immunodeficiency states or significantly impaired bone marrow function.

Age- and Condition-Based Restrictions

• Pediatric Population: Use is not recommended for patients under 18 years old, as safety and efficacy in this age group have not been established by regulators.
• Adults (18+): Use is established for adult patients with active rheumatoid arthritis and psoriatic arthritis.
• Reproductive Restriction: Men intending to father a child should consult with a provider regarding reliable contraception and may need to undergo an accelerated drug elimination procedure.

Official Regulatory Interaction Profile

The official interaction profile for Лефомид (Leflunomide) is defined by both pharmacokinetic and pharmacodynamic restrictions established in government regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with Teriflunomide is formally prohibited as it is the primary active metabolite. Due to the potential for immunosuppression, the administration of Live Attenuated Vaccines is generally not recommended.

Combination with other Hepatotoxic DMARDs (e.g., Methotrexate) is considered not advisable due to the officially described increased risk of severe, additive liver and blood toxicity. Additionally, the consumption of Alcohol must be avoided due to the documented risk of increased hepatotoxicity.

Pharmacokinetic and Procedural Constraints

The active metabolite of Лефомид is a documented inhibitor of the CYP2C9 enzyme, a pharmacokinetic interaction that may alter the plasma levels of co-administered substrates, including Warfarin and Phenytoin.

Due to the prolonged elimination half-life, a mandatory drug elimination procedure (washout) utilizing binding agents such as Cholestyramine or Activated Charcoal is required upon discontinuation before switching to new therapies or in specific clinical situations.

Caution is also advised for co-use with Neurotoxic Medications due to an officially noted increased risk of peripheral neuropathy.

Targeting a Core Metabolic Enzyme

Лефомид's active form acts as a reversible inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). This enzymatic action is a key step in the cellular de novo pyrimidine synthesis pathway, which provides the nucleotides necessary for generating new DNA and RNA. The inhibition limits the intracellular pool of pyrimidine building blocks, thereby influencing cell replication.

---

️ Influencing Immune Cell Proliferation

This disruption of pyrimidine synthesis is most pronounced in highly active, rapidly dividing T-lymphocytes, which are highly dependent on the de novo pathway for growth. By restricting the availability of genetic material components, the drug acts to suppress the proliferation and clonal expansion of these cells. This mechanism leads to a reduction in the number of mitotic T-lymphocytes and alters the population dynamics of immune cells.

---

️ Modulating Systemic Immunity

The suppression of immune cell proliferation and the resulting decrease in their metabolic output modulate the overall activity of the body’s defense system. This cellular action alters the production and release of various downstream mediators, influencing systemic inflammatory signaling patterns and contributing to a regulated physiological state.

How to Use Лефомид — General Administration Guidelines

Лефомид (Leflunomide) is administered through the oral route for systemic absorption and is always taken once daily. The tablets must be swallowed whole with sufficient liquid, and intake is permissible with or without food, as absorption is not significantly affected.

The administration of Лефомид follows a structured, long-term protocol and must be initiated and supervised by a specialist experienced in treating the relevant conditions.

---

Dosing Regimen

Treatment typically begins with an optional loading dose of 100 mg once daily for three days; this regimen is used to more quickly achieve the drug's therapeutic concentration in the body. Following the loading period, the treatment transitions to the maintenance dose. The standard maintenance dose is 20 mg taken once per day. If the 20 mg dose is not tolerated, the dose may be reduced to 10 mg once daily.

---

Key Procedural and Population Rules

Dose Adjustment and Discontinuation: The active component of the drug remains in the body for an extended period. Because of this, an accelerated drug elimination procedure (or washout) is recommended after discontinuing therapy.

Age-Group Administration: Older adults typically do not require a dose adjustment, but the drug is not generally recommended for use in patients under 18 years of age.

Research Evidence / Overview of Studies for Лефомид

---

Evidence for Use in Active Rheumatoid Arthritis (RA)

Research exploring Лефомид was evaluated in active Rheumatoid Arthritis and includes several large-scale Randomized Controlled Trials (RCTs). These studies explored outcomes related to physical discomfort and daily functioning. Trials reported that patterns of change in these clinical scores were observed in the study populations. Some trials described that patterns of change in measurements related to structural joint damage were different in the Лефомид group compared to a placebo group over the study period. Follow-up durations were limited for the initial core RCTs, often lasting up to two years.

---

Evidence for Use in Active Psoriatic Arthritis (PsA)

Лефомид was studied for its use in Psoriatic Arthritis (PsA). Researchers conducted short-term RCTs, where they monitored outcomes related to joint inflammation and skin outcomes. Studies reported how symptoms evolved in the observed populations, with research highlighting changes measured during the study period. The evidence exploring this indication is less broadly established than the evidence available for Rheumatoid Arthritis. The sample sizes were modest, and there is limited information for long-term outcomes specific to PsA.

---

Long-Term Studies and Follow-Up Data

Long-term outcomes are not fully established by the initial controlled trials. Information regarding the long-term use of Лефомид is often derived from observational settings which track patients over extended periods. Data show patterns related to how individuals remained on treatment, but the evidence does not provide full insight into the frequency of all potential long-term events.

---

What Is Still Uncertain About Лефомид

Comparative evidence is lacking for many of the newer, targeted therapies available today. This means that direct head-to-head comparisons are not always available to fully understand patterns in measured outcomes. Also, long-term effects are not fully established. The evidence quality varies across studies, and further research is ongoing to refine the understanding of how symptoms evolved in the observed populations.

Key Studies & References Efficacy and safety of leflunomide in psoriatic arthritis

Common questions about Лефомид (FAQ)

Q: What is the most common reason Azithromycin is prescribed?

Azithromycin is primarily prescribed to treat bacterial infections. This includes common upper and lower respiratory tract infections, certain skin infections, and sexually transmitted infections. It is an antibiotic with a broad spectrum of activity, which means it is indicated for a wide range of bacterial infections.

Q: Can I stop taking Azithromycin as soon as I feel better?

Official guidance recommends completing the entire course of treatment exactly as prescribed by a healthcare professional. Stopping early, even if symptoms improve, may allow remaining bacteria to survive and potentially lead to antibiotic resistance. Completing the full course is generally recommended to help fully resolve the infection and reduce the risk of developing antibiotic resistance.

Q: Is Azithromycin safe to take if I am pregnant?

Current labeling indicates that animal studies have not shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. A healthcare provider should be consulted to discuss the potential benefits and risks before use during pregnancy, as they are best equipped to determine appropriate treatment options.

Q: What are the most serious side effects I should watch out for?

While many side effects are mild (like diarrhea or nausea), serious side effects require immediate medical attention. These may include severe allergic reactions (difficulty breathing, swelling), severe skin reactions, and heart rhythm problems (like QT prolongation). If any severe or concerning symptoms are experienced, immediate medical attention should be sought, such as contacting a healthcare provider or emergency services. Do not discontinue a prescribed medication without first speaking to a professional.

Q: How long does Azithromycin take to start working?

Azithromycin typically begins working quickly after the first dose. However, noticeable improvement in symptoms usually takes 1 to 2 days, and it may take a few more days after completing the course for the infection to fully resolve. Following the full prescribed dosing schedule is important for the treatment to be effective.

Storage Requirements

Leflunomide tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be stored in its original container and kept tightly closed to protect it from moisture. It is a mandatory requirement that the medicine must be protected from light and must not be frozen. All unused medication must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unneeded Лефлуномид must be disposed of according to official guidelines. It is explicitly stated that the medicine must not be disposed of via wastewater or household waste to prevent environmental contamination. Patients should consult a pharmacist or healthcare professional for instructions on utilizing local drug take-back programs.